Bernstein said Biocon Ltd and Mankind Ltd are its non-consensus 'Underperform' stock ideas. It called Aurobindo Pharma as ...

In the past 12 trading days, the market price of Biocon has appreciated by 20 per cent from a level of ₹349.65 on the BSE on April 24, 2026: Biocon Shares ...

Daily Calls on BTTV: Jain advises the caller to exit infra stocks and shift to Biocon.

Bengaluru-based Biocon said that its Q4 profit stood at ₹198.6. The profit was hit by an exceptional item outgo of ₹80.4 crore on various heads, including the impact of the new labour code.

Biocon's transformative journey under Kiran Mazumdar-Shaw highlights a significant succession plan and corporate restructuring for future growth.

Biocon Biologics has been positioning itself to become a global player in biosimilar drugs. Viatris, a longtime partner to Biocon, is charting a course for its future that does not include biosimilars ...

Candidemia is a bloodstream inflection of serious proportions caused by Candida yeast, and is the fourth-most common ...

The biotech major embarks on a future-focussed vision, with the succession plan in place ensuring seamless leadership ...

Other pharma stocks, including Wockhardt Ltd, Lupin Ltd, Divi's Laboratories Ltd, Zydus Lifesciences Ltd, Torrent ...

Net profit before exceptional items rose 64 percent year-on-year to Rs.179 crore, indicating improving underlying earnings momentum.

At the time of filing this report, the stock of the Bangalore-based company was trading at Rs 240.10 apiece on the BSE, down ...

The biosimilar fracas targeting AbbVie’s megablockbuster Humira is taking shape. But to Biocon Biologics CEO Shreehas Tambe, the battle doesn’t solely revolve around market share. Humira, also known ...